Cancer Annihilated: DARZALEX FASPRO® Regimen Unlocks Near-Perfect Survival in Myeloma Battle!

Groundbreaking Victory: A DARZALEX FASPRO®-based regimen achieved a stunning 95% progression-free survival at four years for newly diagnosed, transplant-eligible multiple myeloma patients who maintained deep, sustained cancer cell eradication (MRD negativity).
Unprecedented Hope: Data from the PERSEUS and CEPHEUS studies, unveiled at the 2025 ASCO Annual Meeting, signal a paradigm shift, showing the regimen’s power to delay disease progression or death across patient types.
Eradicating the Enemy: More than half of transplant-eligible patients on the DARZALEX FASPRO®-based treatment saw no detectable cancer cells for at least two years, showcasing a profound and lasting response against this relentless blood cancer.

In a stunning breakthrough against multiple myeloma, a formidable blood cancer long deemed incurable, Johnson & Johnson today revealed data that could rewrite the future for newly diagnosed patients. Findings from the pivotal PERSEUS and CEPHEUS studies showcase the extraordinary power of a DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen, demonstrating its ability to drive cancer cells into deep, sustained remission and dramatically improve long-term survival.

For transplant-eligible patients, the addition of DARZALEX FASPRO® to standard therapy, followed by an investigational DARZALEX FASPRO®-lenalidomide maintenance, led to an astonishing 95.3 percent progression-free survival (PFS) at four years for those achieving sustained minimal residual disease (MRD) negativity—meaning no cancer cells were detected in 100,000 bone marrow cells for at least 24 months. This deep eradication was more than doubled compared to the standard approach⁷. "The depth and durability of MRD negativity observed—paired with unprecedented progression-free survival at four years—underscore the long-term benefit the DARZALEX-based regimen can offer patients early in their treatment journey," declared a lead investigator.

Daratumumab, the core of this regimen, is a monoclonal antibody precision-engineered to hunt and destroy multiple myeloma cells by targeting the CD38 molecule on their surface^{1, 5}. The co-formulation with hyaluronidase ingeniously enhances its delivery, allowing for quicker, more efficient subcutaneous administration^{1, 2}.

The CEPHEUS study further reinforced these triumphant results in transplant-ineligible patients, including older and frailer individuals, proving that adding DARZALEX FASPRO® significantly deepens responses and prolongs life, with 69 percent remaining progression-free at 54 months versus 48 percent with standard care⁷. These consistent, powerful outcomes across diverse patient populations are cementing DARZALEX FASPRO® as a cornerstone in the frontline assault against multiple myeloma, offering a new dawn of hope and the potential for significantly longer, healthier lives. Learn more about these advancements at Johnson & Johnson and DARZALEX FASPRO®.

Cancer Annihilated: DARZALEX FASPRO® Regimen Unlocks Near-Perfect Survival in Myeloma Battle!

References

Stay Updated!